IP Library Patent Application 12366866
Patent Application
App. No. 12/366,866

Compositions Comprising Nebivolol

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/366,866
Abstract

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

Claims (11)

1 - 36 . (canceled)

37 . A composition comprising nebivolol or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof.

38 . The composition of claim 37 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, form a single oral dosage form.

39 . A method of treating or preventing hypertension in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof.

40 . The method of claim 39 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered.

41 . The method of claim 39 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered in a single dosage form.

42 . The method of claim 39 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered in separate dosage forms.

43 . A method of treating or preventing cardiovascular disease in a patient in need thereof, comprising administering to said patient an effective amount of nebivolol or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof.

44 . The method of claim 43 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered.

45 . The method of claim 43 , wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered in a single dosage form.

46 . The method of claim 43 , wherein the wherein the nebivolol or pharmaceutically acceptable salt thereof, and valsartan or pharmaceutically acceptable salt thereof, are orally administered in separate dosage forms.

Assignments (4)
PATENT RELEASE Recorded Nov 18, 2011
From: JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: DEY PHARMA, L.P. (F/K/A DEY, L.P.); MYLAN INC.; MYLAN TECHNOLOGIES, INC.; MYLAN PHARMACEUTICALS, INC.
Reel/Frame 027302/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2010
From: MYLAN INC.
To: FOREST LABORATORIES HOLDINGS LIMITED
Reel/Frame 024878/0683 →
SECURITY AGREEMENT Recorded Jun 14, 2010
From: MYLAN INC.; DEY PHARMA, L.P.; DEY, INC.; MYLAN TECHNOLOGIES, INC.; MYLAN PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 024532/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2009
From: DAVIS, ERIC; O'DONNELL, JOHN; BOTTINI, PETER
To: MYLAN PHARMACEUTICALS, INC.
Reel/Frame 022651/0707 →